アブストラクト
| Title | 透析患者での貧血コントロールにおけるESAとHIF-PH阻害薬の使い分けは? |
|---|---|
| Subtitle | 特集 現場のもやもやをスッキリ除く 透析患者のくすりの疑問 透析合併症の疑問 |
| Authors | 関桃子, 星野純一 |
| Authors (kana) | |
| Organization | 東京女子医科大学腎臓内科 |
| Journal | 月刊薬事 |
| Volume | 65 |
| Number | 12 |
| Page | 2414-2416 |
| Year/Month | 2023 / 9 |
| Article | 報告 |
| Publisher | じほう |
| Abstract | [Answer] 透析患者では, 慢性腎不全によるエリスロポエチン(EPO)の産生低下のほか, 透析回路への失血などさまざまな要因で貧血となりやすい. 赤血球造血刺激因子製剤(ESA)と低酸素誘導因子プロリン水酸化酵素(HIF-PH)阻害薬はどちらもEPO作用による造血を促進するが, ESAは透析回路への注射により投与する一方, HIF-PH阻害薬は経口薬剤であることが特徴である. また, HIF-PH阻害薬は鉄利用を改善させるため特に鉄利用障害に伴うESA抵抗性の症例で効果が期待されるが, HIFの下流にある血管内皮細胞増殖因子(VEGF)の活性化による網膜疾患や悪性腫瘍, 血栓塞栓症などの副作用が懸念されており, 治療開始前の合併症の評価が推奨される. |
| Practice | 薬学 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に803円(税込) です。
参考文献
- 1) Mercadal L, et al; NephroTest Study Group: Timing and determinants of erythropoietin deficiency in chronic kidney disease. Clin J Am Soc Nephrol, 7: 35-42, 2012
- 2) 日本透析医学会・編: 2015年版 慢性腎臓病患者における腎性貧血治療のガイドライン. 日本透析医学会雑誌, 49: 89-158, 2016
- 3) Lau JH, et al: Impact of haemoglobin and erythropoietin dose changes on mortality: a secondary analysis of results from a randomized anaemia management trial. Nephrol Dial Transplant, 25: 4002-4009, 2010
- 4) Inaba M, et al: Disappearance of association in diabetic patients on hemodialysis between anemia and mortality risk: the Japan dialysis outcomes and practice pattern study. Nephron Clin Pract, 120: c91-c100, 2012
- 5) Maekawa K, et al: Influence of atherosclerosis on the relationship between anaemia and mortality risk in haemodialysis patients. Nephrol Dial Transplant, 23: 2329-2336, 2008
残りの16件を表示する
- 6) Miyake T, et al: Purification of human erythropoietin. J Biol Chem, 252: 5558-5564, 1977
- 7) Gupta N, et al: Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD. Am J Kidney Dis, 69: 815-826, 2017
- 8) 日本腎臓学会: HIF-PH阻害薬適正使用に関するrecommendation. 日本腎臓学会誌, 62: 711-716, 2020
- 9) Tang M, et al: Safe and Effective Treatment for Anemic Patients With Chronic Kidney Disease: An Updated Systematic Review and Meta-Analysis on Roxadustat. Front Pharmacol, 12: 658079, 2021
- 10) Eckardt KU, et al: Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis. N Engl J Med, 384: 1601-1612, 2021
- 11) Zheng Q, et al: Efficacy and Safety of Daprodustat for Anemia Therapy in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis. Front Pharmacol, 11: 573645, 2021
- 12) Yamamoto H, et al: Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study. Am J Nephrol, 52: 884-893, 2021
- 13) Fujikawa R, et al: Treatment of anemia associated with chronic kidney disease with the HIF prolyl hydroxylase inhibitor enarodustat: A review of the evidence. Ther Apher Dial, 26: 679-693, 2022
- 14) Yap DYH, et al; APSN HIF-PHI Recommendation Committee: Recommendations by the Asian Pacific society of nephrology(APSN)on the appropriate use of HIF-PH inhibitors. Nephrology(Carlton), 26: 105-118, 2021
- 15) Hung SC, et al: Erythropoiesis-stimulating agents in chronic kidney disease: what have we learned in 25 years? J Formos Med Assoc, 113: 3-10, 2014
- 16) Pfeffer MA, et al; TREAT Investigators: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med, 361: 2019-2032, 2009
- 17) Singh AK, et al; CHOIR Investigators: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med, 355: 2085-2098, 2006
- 18) Drueke TB, et al; CREATE Investigators: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med, 355: 2071-2084, 2006
- 19) Bohlius J, et al: Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet, 373: 1532-1542, 2009
- 20) Hamano T, et al: Thresholds of iron markers for iron deficiency erythropoiesis-finding of the Japanese nationwide dialysis registry. Kidney Int Suppl(2011), 5: 23-32, 2015
- 21) Streja E, et al: Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis. Am J Kidney Dis, 52: 727-736, 2008
